A 10-year-old Golden Retriever diagnosed with histiocytic sarcoma. Treatment began based on medical literature that suggested the tumor could bear KRAS and PTPN11 mutations, which are associated with response to the targeted drug cobimetinib, after an intial course of radiation therapy.
A SearchLight DNA™ test revealed absence of KRAS or PTPN11 mutations and presence instead of a mutation that suggested cobimetinib resistance. The treatment plan was switched to only radiation therapy and sirolimus.
Nine months after diagnosis, the patient was enjoying a high quality of life.
Hematoxylin and eosin (H&E) stain
Histologically, the neoplasm is composed of spindle cells that have large round to reniform nuclei with 1 to 3 prominent nucleoli and exhibit frequent karyomegaly. The background shows moderate numbers of small lymphocytes.
By analyzing the DNA of your pet’s tumor cells, Vidium’s SearchLight DNA™ can inform your veterinary team about what mutations might exist within that tumor, what is driving the tumor’s growth, and what treatments might be effective to help make your dog well again.